Key points from article :
Neuralink’s cofounder, Max Hodak, left in 2021 under mysterious circumstances.
Last year, he secured $47 million in funding for a brain interface venture called Science Corp.
Now he’s personally invested in another Neuralink rival, Synchron.
Hodak previously served on an advisory board for the company.
Synchron accesses the brain via blood vessels and leaves electrodes in the walls of the vasculature.
Removes the need to "[penetrate] into the sensitive bulk tissue of the brain,” says Hodak.
The company has also already begun human trials for its device.